



**World Health
Organization**

INN Working Document 18.435
31/05/2018

**Addendum¹ to
"The use of stems in the selection of International
Nonproprietary names (INN) for pharmaceutical
substances" WHO/EMP/RHT/TSN/2013.1**

Programme on International Nonproprietary Names (INN)

***Technologies Standards and Norms (TSN)
Regulation of Medicines and other health technologies (RHT)***

World Health Organization, Geneva

© World Health Organization 2018 - All rights reserved. The contents of this document may not be reviewed, abstracted, quoted, referenced, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means, without explicit prior authorization of the WHO INN Programme.

This document contains the collective views of the INN Expert Group and does not necessarily represent the decisions or the stated policy of the World Health Organization.

Addendum¹ to "The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances" - WHO/EMP/RHT/TSN/2013.1

¹ This addendum is a cumulative list of all new stems selected by the INN Expert Group since the publication of *"The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances"* 2013.

-apt- aptamers, classical and mirror ones

(a) avacincaptad pegol (113), egaptivon pegol (111), emapticap pegol (108), lexaptetid pegol (108), olapteted pegol (109), pegaptanib (88)

(b) -*vaptan* stem: balovaptan (116), conivaptan (82), lixivaptan (83), mozavaptan (87), nelivaptan (98), relcovaptan (82), ribuvaptan (110), satavaptan (93), tolvaptan (83). Others: aptazapine (50), aptiganel (72), aptocaine (21), captamine (18), captodiame (06), captopril (39), danegaptide (101), daptomycin (58), icrocaptide (89), mercaptamine (01), mercaptomerin (01), mercaptopurine (06), naptumomab estafenatox (96), rotigaptide (94), sodium borocaptate (¹⁰B) (62), sodium stibocaptate (17), taplitumomab paptox (84)

(c) pegnivacogin (106)

-catib cathepsin inhibitors

balicatib (92), dutacatib (94), odanacatib (98), petesicatib (117), relacatib (95)

-cel cell therapy

Please refer to the Annex "General policies for cell therapies".

adimlecleucel (117), audencel (115), axicabtagene ciloleucel (117), baltaleucel (116), cenplacel (115), darvadstrocel (117), eltrapuldencel (115), emiplacel (117), evagenretcel (116), ilixadencel (116), lifileucel (118), nalotimagene carmaleucel (118), palucorcel (115), rivogenlecleucel (117), spanlecortemlocel (112 amendment in 115), tabellecleucel (117), tisagenlecleucel (117), tonogenconcel (115), vadacabtagene leraleucel (117), vandefitemcel (115)

-cetrapib cholesteryl ester transfer protein (CETP) inhibitors

anacetrapib (98), dalcetrapib (96), evacetrapib (105), obicetrapib (115), torcetrapib (87)

-degib SMO receptor antagonists

glasdegib (111), patidegib (111), sonidegib (107), taladegib (110), vismodegib (103)

-domide antineoplastics, thalidomide derivatives

avadomide (117), endomide (40), iberdomide (117), lenalidomide (91), mitindomide (70), pomalidomide (97), thalidomide (08)

-dotin synthetic derivatives of dolastatin series

amadotin: lupartumab amadotin (115)
cemadotin (75)
ixadotin: aprutumab ixadotin (115)
mafodotin: belantamab mafodotin (118), denintuzumab mafodotin (111), depatuxizumab mafodotin (115), vorsetuzumab mafodotin (107)
pelidotin: cofetuzumab pelidotin (117)
soblidotin (84)
tasidotin (93)
vedotin: azintuxizumab vedotin (116), brentuximab vedotin (103), enapotamab vedotin (118), enfortumab vedotin (109), glembatumumab vedotin (113), iladatuzumab vedotin (117), indusatumab vedotin (112), ladiratuzumab vedotin (117), lifastuzumab vedotin (110), losatuxizumab vedotin (116), pinatuzumab vedotin (108), polatuzumab vedotin (108), samrotamab vedotin (118), sirtratumab vedotin (117), sofituzumab vedotin (110), tisotumab vedotin (113), telisotuzumab vedotin (115), vandortuzumab vedotin (113)

-fenacin muscarinic receptor antagonists

afacifenacin (101), darifenacin (70), imidafenacin (90), revefenacin (114), solifenacin (85), tarafenacin (100), tofenacin (15), zamifenacin (68)

-fensine **norepinephrine, serotonin, dopamine reuptake inhibitors**

brasofensine (76), diclofensine (44), liafensine (109), nomifensine (24),
perafensine (44), tesofensine (89)

-gepant **calcitonin gene-related peptide receptor antagonists**

atogepant (116), olcegepant (86), rimegepant (109), telcagepant (100),
ubrogepant (109)

-glurant **metabotropic glutamate receptor antagonists / negative allosteric
modulators**

basimglurant (109), decoglurant (109), dipraglurant (102), mavoglurant (104),
raseglurant (102), remeglurant (109)

-imod immunomodulators, both stimulant/suppressive and stimulant

-tolimod **toll-like receptors (TLR) agonists**

agatolimod (98), cobitolimod (113), entolimod (108), lefitolimod (113),
motolimod (112), rintatolimod (102), telratolimod (118), tilsotolimod (117),
vesatolimod (113)

-isant **histamine H₃ receptor antagonists**

bavisant (103), cipralisant (85), enerisant (113), irdabisant (105), pitolisant
(100)

-laner **antagonists of GABA (gamma-aminobutyric acid) regulated
chloride channels, antiparasitic agents**

afoxolaner (108), fluralaner (107), lotilaner (110), sarolaner (111),
tigolaner (117)

-mab	monoclonal antibodies
-vet-	veterinary use
	blontuvmab (114), frunevetmab (116), gilvetmab (116), ranevetmab (115), tamtuvetmab (114)

-nepag	prostaglandins receptors agonists, non-prostanoids
(a)	aganepag (104), evatanepag (101), omidenepag (114), ralinepag (112), simenepag (103), taprenepag (103)
(c)	selexipag (102)

-orexant	orexin receptor antagonists
	almorexant (98), filorexant (108), lemborexant (111), nemorexant (118), seltorexant (115), suvorexant (105)

-prazan	proton pump inhibitors, not dependent on acid activation
	abeprazan (118), linaprazan (92), revaprazan (91), soraprazan (88), tegoprazan (113), vonoprazan (106)

-rafenib	Raf (rapidly accelerated fibrosarcoma) kinase inhibitors
	agerafenib (115), belvarafenib (118), dabrafenib (105), encorafenib (109), lifirafenib (117), sorafenib (88), regorafenib (100), vemurafenib (103)

-siban	oxytocin antagonists
	atosiban (60), barusiban (88), cligosiban (118), epelsiban (105), nolasiban (114), retosiban (98)

-siran small interfering RNA

asvasiran (111), bamosiran (106), bevasiranib (108), cemdisiran (114),
cosdosiran (116), fitusiran (113), givosiran (115), inclisiran (115), lumasiran
(117), patisiran (109), revusiran (111), teprasiran (116), tivanisiran (116),
votrisiran (117)

-stat enzymes inhibitors

-dustat hypoxia inducible factor (HIF) prolyl hydroxylase inhibitors

daprodustat (113), desidustat (117), enarodustat (117), molidustat (108),
roxadustat (108), vadadustat (114)

-gacestat gamma-secretase inhibitors

avagacestat (104), begacestat (97), crenigacestat (117), nirogacestat (115),
semagacestat (99)

-tansine maytansinoid derivatives, antineoplastics

emtansine (such as laprituximab emtansine (114), naratuximab emtansine
(114) , trastuzumab emtansine (103))

maitansine (40)

mertansine (such as cantuzumab mertansine (105), lorvotuzumab mertansine
(103))

ravtansine (such as anetumab ravtansine (109), cantuzumab ravtansine (105),
coltuximab ravtansine (109), indatuximab ravtansine (105))

soravtansine (such as mirvetuximab soravtansine (113))

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_25801

